| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454887 | Lung Cancer | 2015 | 34 Pages |
Abstract
Romidepsin 8Â mg/m2 plus erlotinib appears well tolerated, has evidence of disease control, and exhibits effects on relevant molecular targets in an unselected advanced NSCLC population.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
David E. Gerber, David A. Boothman, Farjana J. Fattah, Ying Dong, Hong Zhu, Rachel A. Skelton, Laurin L. Priddy, Peggy Vo, Jonathan E. Dowell, Venetia Sarode, Richard Leff, Claudia Meek, Yang Xie, Joan H. Schiller,